BSA<
Sponsors
NPO Hokkaido Gastrointestinal Cancer Study Group (HGCSG), Fukuoka Tumor Research(FUTURE), The University of Tokyo Hospital, Hokkaido Pancreatic Cancer Study Group (HOPS)
Conditions
Borderline and Locally advanced pancreatic cancerColorectal CancerPancreatic cancerUnresectable or recurrent biliary tract canceradvanced/metastatic colorectal cancerpancreatic cancer
Phase 2
Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer
Active, not recruitingJPRN-UMIN000004882
Start: 2010-03-01Target: 80Updated: 2026-06-29
Phase II study of S-1 plus irinotecan combined with biweekly cetuximab as 2nd-line chemotherapy in patients with wild type KRAS unresectable colorectal cancer, who had previously received oxaliplatin-based chemoterapy without CV port. (FUTURE 1103 STUDY)
Active, not recruitingJPRN-UMIN000006823
Start: 2011-12-01Target: 30Updated: 2026-06-29
A phase 2 study of combination therapy with gemcitabine S-1 and leucovorin in patients with pancreatic cancer
Active, not recruitingJPRN-UMIN000010720
Start: 2013-05-15Target: 49Updated: 2026-06-29
Phase II study of gemcitabine, S-1, leucovorin combination therapy for advanced biliary tract cancer
Active, not recruitingJPRN-UMIN000010678
Start: 2013-06-01Target: 45Updated: 2026-06-29
A phase 2 study of combination neoadjuvant chemotherapy with gemcitabine S-1 and leucovorin in patients with borderline and locally advanced pancreatic cancer
Active, not recruitingJPRN-UMIN000012480
Start: 2013-12-04Target: 24Updated: 2026-06-29
Neoadjuvant S-1 therapy for resectable pancreatic cancer patients; A phase2 study
Active, not recruitingJPRN-UMIN000013031
Start: 2013-11-01Target: 50Updated: 2026-06-29